A randomized, double-blinded placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of Efgartigimod PH20 SC Administered by prefilled syringe in adults participants with ocular MG

drug protocol number
ARGX-113-2315
drug sponsor
Argenx BV / Balsam
drug study
Efgartigimod
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase